Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)
US12252540B2 · kind B2 · utility
0Cited by
75References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 27, 2021 |
| Grant date | Mar 18, 2025 |
| Priority date | — |
| Expiry date | Aug 31, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.